The Baxter and Amgen-backed genome editing technology developer floated in the middle of its range and is now valued at more than $780m.

Precision BioSciences, a US-based genome editing technology developer that counts pharmaceutical companies Amgen and Baxter as investors, raised more than $126m in its initial public offering last week.

The offering consisted of 7.9 million shares issued on the Nasdaq Global Select Market priced at $16.00 each, in the middle of its $15 to $17 range, valuing the company at approximately $784m.

Founded in 2006 and spun out of Duke University, Precision Bio is working on genome editing technology in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn